We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Optimvia to leverage Ginkgo's cell and enzyme engineering platform to improve the performance of Optimvia's biosynthetic heparin manufacturing technology.
In May 2021, the healthcare industry reported 90 deals worth $25.7 billion as compared to the last 12-month average (May 2020 to April 2021) of101 deals worth $22.4 billion.
Biogen has entered into a new collaboration with Ginkgo Bioworks to develop a novel gene therapy manufacturing platform to ‘redefine the industry standard’ for manufacturing AAV-based vectors.